WOCKPHARMANSEWockhardt Limited· PharmaceuticalsHighNeutral
Announced Mon, 4 May · 15:29 IST

Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2026-27/006 dated 28th April, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, inter-alia, has approved:i. the Audited Financial Results and Financial Statements (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2026. Kindly find enclosed herewith:a. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2026 along with Audit Report issued by M/s. M S K C & Associates LLP, Statutory Auditors of the Company on the same (enclosed as Annexure I); and b. Declaration on unmodified opinion on Audit Report (enclosed as Annexure II) ii Enabling proposal for raising of funds by issue of equity shares / securities convertible into equity shares/ non-convertible securities or any combination thereof in one or more tranches of public and/or private offerings, Qualified Institutions Placement and/or on preferential allotment basis or any combination thereof or any other method as may be permitted under applicable law, subject to consent of the shareholders at the ensuing Annual General Meeting and such approvals and compliances as may be required.

Revenue Growth 20pctNegative Operating CashflowExceptional ItemResults View source PDF

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+17.4%1-day move
₹1431.00
prior close
₹1500.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.8+4.6+4.1+2.4+17.4+14.0+12.5+13.6+9.7+8.0+19.9+34.5+34.0
Up moveDown movePending
AI summary

Wockhardt Limited reported strong FY2026 results with standalone revenue up 24% to Rs 1,739 crore from Rs 1,402 crore. The company swung to standalone profit after tax of Rs 317 crore versus a loss of Rs 12 crore in FY25. Consolidated revenue grew 12% to Rs 3,373 crore with PAT of Rs 199 crore versus a loss of Rs 57 crore previously. Key exceptional items include Rs 35 crore gain from Dr. Reddy's settlement and Rs 110 crore charge from deconsolidation of US subsidiaries (net Rs 85 crore charge). The Board also approved an enabling proposal to raise funds via equity, convertible securities, QIP or preferential allotment, subject to shareholder approval. Auditors gave an unmodified opinion.

Likely market impact

The turnaround from losses to profitability and strong revenue growth are positives for shareholders. The fund-raising proposal may dilute equity but could strengthen the balance sheet. Cash flow turned positive at Rs 241 crore standalone versus negative Rs 14 crore last year.